Contact Information

*Daniel Kremer is not licensed to practice law. His activities are directly supervised by members of the firm licensed to practice law in the firm’s Irvine office.

Daniel Kremer concentrates on patent prosecution concerning oncology, cell therapies and immunotherapy matters. Before private practice, Daniel was a postdoctoral researcher and postdoctoral research fellow at The Scripps Research Institute in San Diego. Daniel has contributed to 18 peer-reviewed scientific publications and is a co-inventor of a small molecule pharmaceutical patent application for the treatment of rare blood cancers. 

Thought Leadership

  • Co-inventor, WO 2022/251788 A1
  • Co-Author, “Targeting allosteric regulation of cancer metabolism,” Nature Chemical Biology., April 2022.
  • Co-Author, “Cancer SLC43A2 alters T cell methionine metabolism and histone methylation,” Nature, September 2020 
  • Co-Author, “Cysteine depletion induces pancreatic tumor ferroptosis in mice,” Science, April 2020. 
  • Co-Author, “Histone Acetyltransferase MOF Blocks Acquisition of Quiescence in Ground-State ESCs through Activating Fatty Acid Oxidation,” Cell Stem Cell, June 2020. 
  • Co-Author, “Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer,” Cell Metab., June 2019.  
  • Co-Author, “IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response,” Science Translational Medicine, January 2018.
  • Co-Author, “Pancreatic stellate cells support tumor metabolism through autophagic alanine secretion,” Nature., August 2016.